Proteome Sciences plc (LON:PRM)‘s stock had its “corporate” rating reiterated by equities researchers at FinnCap in a research note issued to investors on Tuesday. They currently have a GBX 12 ($0.15) price target on the stock. FinnCap’s target price would indicate a potential upside of 104.26% from the company’s previous close.

Proteome Sciences plc (LON:PRM) opened at 5.695 on Tuesday. The firm’s market cap is GBX 12.98 million. Proteome Sciences plc has a 52-week low of GBX 5.00 and a 52-week high of GBX 23.94. The stock has a 50 day moving average price of GBX 7.59 and a 200 day moving average price of GBX 13.35.

COPYRIGHT VIOLATION WARNING: This article was first reported by Daily Political and is the propert of of Daily Political. If you are viewing this article on another website, it was illegally copied and reposted in violation of US and international trademark & copyright law. The original version of this article can be accessed at http://www.dailypolitical.com/2016/12/01/proteome-sciences-plc-prm-rating-reiterated-by-finncap.html.

In other news, insider Roger Steven McDowell bought 2,000,000 shares of the company’s stock in a transaction on Friday, November 4th. The shares were purchased at an average price of GBX 5 ($0.06) per share, with a total value of £100,000 ($124,054.09).

About Proteome Sciences plc

Proteome Sciences plc is a protein biomarker company specializing in proteomics and peptidomics services and applications, and mass spectrometry (MS) protein analysis. The Company is engaged in biomarker research and development in applied proteomics and workflows using its techniques to detect and characterize differentially expressed proteins in diseases for diagnostic, prognostic and therapeutic applications.

Receive News & Ratings for Proteome Sciences plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteome Sciences plc and related companies with MarketBeat.com's FREE daily email newsletter.